Navigation Links
Nuvasive Reports Third Quarter 2008 Financial Results
Date:10/22/2008

ive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause Company's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the risk that the Company's revenue or profitability projections may prove incorrect because of unexpected difficulty in generating sales or achieving anticipated profitability; the risk that Company may encounter unanticipated difficulty integrating the Osteocel product into its product line and may be unable to generate expected revenues or profitability from Osteocel; the uncertain process of seeking regulatory approval or clearance for Company's products or devices, including risks that devices currently under development or in clinical studies (such as NeoDisc(R)) may not be approved for commercial sale; the risk that the ongoing patent litigation with Medtronic could result in a substantial judgment or settlement obligation; the possibility that the FDA may require significant changes to Company's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of Company's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in Company's press releases and periodic filings with the Securities and Exchange Commission. Company's public filings with the Securities and Exchange Commission are available at
SOURCE NuVasive, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. NuVasive to Present at Morgan Stanley Global Healthcare Unplugged Conference
2. NuVasive Completes Acquisition of Osteocel Biologics Business
3. NuVasive Announces Web Cast and Conference Call of Second Quarter 2008 Results
4. NuVasive to Present at William Blair 28th Annual Growth Stock Conference
5. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
6. NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference
7. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
8. NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results
9. NuVasive to Host Investor Reception on September 11, 2007
10. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
11. Sangui Biotech International, Inc., Reports Sales Decrease, Continued Losses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 ... market research report is available in its ... Market 2014-2018 http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html ... Biodegradable materials are materials that are readily ... packaging differs from conventional non-degradable packaging in ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 The Global ... in-depth study on the current state of the Trifluoroacetic ... provides a basic overview of the industry, including definitions, ... Chinese domestic market analysis are provided with a focus ... market. A comparison between the international and Chinese situation ...
(Date:8/27/2014)... 27, 2014  Lisa Kulik saw fireworks for the ... holiday, thanks to a groundbreaking retinal implant co-invented by ... clinician-researcher at the University of Southern California (USC) Eye ... Peoria, Ariz. resident who has retinitis pigmentosa, ... sight. On June 2, she became the first person ...
(Date:8/27/2014)... 2014 Guggenheim Securities, the investment banking and ... hiring of veteran equity analyst Charles "Tony" Butler as ... will focus on the biotech/biopharma sector. " ... experience and a broad network of relationships in his ... and Head of Equities at Guggenheim Securities. "His insights ...
Breaking Biology Technology:Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2
... Patients Achieved an Objective Tumor Response by End of ... Inc. (Nasdaq: PPHM ) today reported that ... endpoint in the first stage of its ongoing Phase ... cancer (NSCLC). The open-label, Simon two-stage study is ...
... Bulletin Board: GOVX), an Atlanta-based, publicly traded,biopharmaceutical company developing ... and other infectious agents, today,announced that its Corporate Presentation ... webcast live by Thomson Reuters. The Conference will be ... February 9 and 10, 2009. , ...
... Wis., Feb. 4 Mach One Corporation (Pink Sheets: ... develops biotechnology based solutions that produce positive, long term ... that it has signed a definitive agreement to acquire ... company that supplies ingredients to the food, feed and ...
Cached Biology Technology:Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 2Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 3Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 4GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference 2GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference 3Mach One Corporation Signs Definitive Agreement to Acquire Ceres Organic Harvest, Inc. 2
(Date:8/28/2014)... conserve biodiversity and more action is needed to ensure ... say. , Published in PLOS ONE , researchers ... Exeter, used meta-analysis - combining results from different studies ... research into these areas, to determine whether they actually ... Biological Sciences, said protecting an area from human exploitation ...
(Date:8/27/2014)... Wis. The mechanical force that a single fungal cell ... vanishingly small, but it plays a heavy role in setting ... In fact, it may not be too much of a ... land without the ability to respond to the touch of ... An, a professor of agronomy at the University of Wisconsin-Madison. ...
(Date:8/27/2014)... in understanding the mysteries of the human genome was ... provide the most detailed comparison yet of how the ... , The research, appearing August 28 in in ... encoded in the three species, genomes is "read out," ... chromosomes. , The results add billions of entries to ...
Breaking Biology News(10 mins):Protected areas proven to protect biodiversity 2A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4
... (May 24, 2010) The timing of umbilical cord clamping ... suggest researchers at the University of South Florida,s Center of ... umbilical cord for a slightly longer period of time allows ... infant and, with that critical period extended, many good physiological ...
... , WALL, N.J. , May 24 BIO-key ... identification solutions, today announced that Evidian has integrated BIO-key,s biometric software ... deployed this biometric identification solution at two major pharmaceutical companies. , ... (Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ...
... Israel Current research suggests that T helper-type ... actual inhibit the development of experimental immune encephalomyelitis (EAE), ... Th17 cells. The related report by Wildbaum et ... high CD4 + T cells restrain ...
Cached Biology News:Do we clamp the umbilical cord too soon? 2Do we clamp the umbilical cord too soon? 3BIO-key(R) Biometric Identification Now Incorporated Into Evidian Enterprise Single Sign-On Solution 2BIO-key(R) Biometric Identification Now Incorporated Into Evidian Enterprise Single Sign-On Solution 3BIO-key(R) Biometric Identification Now Incorporated Into Evidian Enterprise Single Sign-On Solution 4When helper cells aren't helpful 2
...
cysteine and glycine-rich protein 2,...
... Antitumour agent and DNA-topoisomersae II inhibitor (IC50 = ... C 29 H 32 O 13 ... Store at: RT ... Solubility: Soluble to 100 ...
HSPBP1 Antibody...
Biology Products: